After 30 years of use in transplant medicine, EBV-specific T cells offer key lessons for safer, scalable allogeneic cell therapies, writes Ivan Horak, M.D.
Candidates for seats on company boards should scrutinize governance, culture, and leadership dynamics before saying yes, ...
Servant leadership means putting people first because results follow people, not the other way around, writes Boehringer ...
On this weeks episode of the Business of Biotech, Philina Lee, Ph.D., CEO at AdvanCell, explains how lead-based targeted alpha therapies can unlock deeper, more durable cancer responses, and why ...
On this weeks episode of the Business of Biotech, Cyriac Roeding talks about cofounding and leading Earli, a "bioAI" company using synthetic DNA switches and cancer-binding lipid nanoparticles to ...
A company launching a drug in the United States in 2027 will hire its contract sales organization (CSO) from a market that has changed since its executives last bought from it. Five of the best-known ...
On this week's episode of the Business of Biotech, Independent Board Director and five-time public company CFO Alan Shaw returns to the show for an update on current biotech financing and the ...
On this week's episode of the Business of Biotech, Alex Aravanis, M.D., Ph.D., CEO of Moonwalk Biosciences, talks about the opportunity in obesity beyond GLP-1s. He describes Moonwalk’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results